New evidence for oxetorone toxicity
| Autor: | Chloé Bruneau, A. Touré, Alain Turcant, M. Deguigne, Gaël Le Roux |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Drug Poison Control Centers Time Factors Adolescent media_common.quotation_subject Suicide Attempted Toxicology 030226 pharmacology & pharmacy Young Adult 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Benzoxepins Humans Medicine Child Aged Retrospective Studies media_common business.industry Antagonist Infant General Medicine Middle Aged chemistry Child Preschool Anesthesia Toxicity Plasma concentration Hypertonia Female Observational study Serotonin Antagonists Serotonin Drug Overdose medicine.symptom Oxetorone business 030217 neurology & neurosurgery |
| Zdroj: | Clinical Toxicology. 55:142-146 |
| ISSN: | 1556-9519 1556-3650 |
| DOI: | 10.1080/15563650.2016.1267358 |
| Popis: | Oxetorone is a serotonin antagonist antimigraine drug but literature relating to its toxic properties is poor. The aim of this study is to describe the toxicological profile of oxetorone and to highlight any relationship between clinical and analytical findings.This is a retrospective and observational study of cases exposure to oxetorone, reported to the Angers Poison and Toxicovigilance Centre between January 2002 and May 2016. Severity was assessed using the Poisoning Severity Score (PSS). Cases where data were incomplete, where oxetorone was deemed not accountable, where clinical signs were linked mainly to a co-ingested drug or where the plasma concentration of oxetorone was negative were all excluded.We included 43 cases of exposure, 31 of whom were suicide attempts. The assumed ingested dose (60-3600 mg) was correlated to severity (rSeveral clinical and paraclinical parameters strongly point towards membrane-stabilising properties of the molecule and the risk of a delayed occurrence of symptoms or a secondary worsening. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|